Alyeska Investment Group L.P. Increases Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Alyeska Investment Group L.P. lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 34.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,000 shares of the biotechnology company's stock after purchasing an additional 40,000 shares during the quarter. Alyeska Investment Group L.P. owned 0.26% of Ascendis Pharma A/S worth $21,339,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. RA Capital Management L.P. lifted its stake in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after buying an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after buying an additional 39,309 shares in the last quarter. Capital International Investors grew its position in Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after acquiring an additional 753,859 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after acquiring an additional 960,504 shares in the last quarter.

Ascendis Pharma A/S Stock Down 5.1 %

Shares of NASDAQ:ASND traded down $8.14 during trading on Friday, hitting $151.25. The stock had a trading volume of 598,469 shares, compared to its average volume of 500,431. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The company has a market capitalization of $9.22 billion, a PE ratio of -21.30 and a beta of 0.41. The firm's fifty day moving average is $156.12 and its 200 day moving average is $141.46.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Equities research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Cantor Fitzgerald lifted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Royal Bank of Canada increased their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Wedbush boosted their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $216.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.